10.57945/MANARA.21598212
Mohamed A. Ismail
Mohamed A.
Ismail
Marzia Vezzalini
Marzia
Vezzalini
Hisham Morsi
Hisham
Morsi
Ahmad Abujaber
Ahmad
Abujaber
Ali Al Sayab
Ali
Al Sayab
Kodappully Siveen
Kodappully
Siveen
Mohamed A. Yassin
Mohamed A.
Yassin
National Center for Cancer Care and Research
Maria Monne
Maria
Monne
Muthanna Samara
Muthanna
Samara
Kingston University
Richard Cook
Richard
Cook
University of Waterloo
University of York
Birkbeck, University of London
University of Leeds
Claudio Sorio
Claudio
Sorio
Helmout Modjtahedi
Helmout
Modjtahedi
Nader I. Al-Dewik
Nader I.
Al-Dewik
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
<p>Protein tyrosine phosphatase receptor gamma (PTPRG) is a member of the receptor-like family protein tyrosine phosphatases and acts as a tumor suppressor gene in different neoplasms. Recent studies reported the down-regulation of PTPRG expression levels in Chronic Myeloid Leukemia disease (CML). In addition, the BCR-ABL1 transcript level is currently a key predictive biomarker of CML response to treatment with Tyrosine Kinase Inhibitors (TKIs). The aim of this study was to employ flow cytometry to monitor the changes in the expression level of PTPRG in the white blood cells (WBCs) of CML patients at the time of diagnosis and following treatment with TKIs. WBCs from peripheral blood of 21 CML patients were extracted at diagnosis and during follow up along with seven healthy individuals. The PTPRG expression level was determined at protein and mRNA levels by both flow cytometry with monoclonal antibody (TPĪ³ B9-2) and RT-qPCR, and BCR-ABL1 transcript by RT-qPCR, respectively. PTPRG expression was found to be lower in the neutrophils and monocytes of CML patients at time of diagnosis compared to healthy individuals. Treatment with TKIs nilotinib and Imatinib Mesylate restored the expression of PTPRG in the WBCs of CML patients to levels observed in healthy controls. Moreover, restoration levels were greatest in optimal responders and occurred earlier with nilotinib compared to imatinib. Our results support the measurement of PTPRG expression level in the WBCs of CML patients by flow cytometry as a monitoring tool for the response to treatment with TKIs in CML patients.</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-021-86875-y" target="_blank">http://dx.doi.org/10.1038/s41598-021-86875-y</a></p>
Oncology and carcinogenesis
Manara - Qatar Research Repository
2022
2022-11-22
2023-01-10
Journal contribution
2012207 Bytes
10.1038/s41598-021-86875-y
CC BY 4.0